Drug Trial Radar · NCT04470050
Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal
Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
225
Actual
Start
Jun 9, 2020
Primary completion
Feb 18, 2021
Study completion Feb 18, 2021
Sponsor
- Lead sponsor
- BioXcel Therapeutics IncIndustry
- Sponsor type
- Industry
- Collaborators
- Cognitive Research Corporation
- First posted
- Jul 14, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 1b/2 inpatient study assessed the safety, pharmacokinetics, and early signs of efficacy of escalating doses of BXCL501 versus placebo following discontinuation of morphine maintenance. The opioid (morphine) maintenance phase (Phase 1b) included Days 1-5; the randomized BXCL501/placebo phase (Phase 2) included Days 6-12. The randomized phase was followed by 2 sequential days, Days 13 and 14, utilizing treatment of BXCL501-placebo sublingual films and morphine-placebo capsules for all subjects who remained in the study.
Conditions
- Opioid Withdrawal
Interventions
DexmedetomidineDrug
Sublingual Film of Dexmedetomidine
PlaceboDrug
Sublingual Placebo film
Primary outcomes
What the sponsor says the trial is designed to measure.
- Peak SOWS Scores at Baseline and Over TimeTime frame: Baseline (pre-dose day 6) and at days 6, 7, 8, 9, 10, 11, 12, 13, and 14 post-dose
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
BioXcel Clinical Research Site
Miami Lakes, Florida
BioXcel Clinical Research Site
Marlton, New Jersey
BioXcel Clinical Research Site
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.